Estrella draws Zacks coverage after 5 of 5 high-dose patients hit CR Zacks cited Phase I EB103 data in 9 patients, including no treatment-related serious adverse events. Why it matters: it assigned a $12 share value.

#ESLA #ESLAW Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research

www.stocktitan.net/news/ESLA/estrella-immun...

Can This New Cancer Therapy Revolutionize NHL Treatment? Early Trial Results Show Promise Promising Phase I/II results for EB103 therapy in NHL patients: clean safety profile, tumor response in all patients, advancing to higher dose cohort.

#ESLA #ESLAW Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

www.stocktitan.net/news/ESLA/estrella-immun...

Can This Revolutionary T-Cell Platform Transform Blood Cancer Treatment? Analysts Think So D. Boral Capital initiates coverage with Buy rating, citing ARTEMIS® platform's potential in B-cell lymphoma. Early trials show promising regulated immune response.

#ESLA #ESLAW Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

www.stocktitan.net/news/ESLA/estrella-immun...